Tenderwize
Retour à la recherche

Non-exclusive drug discount agreement for Dexamethasone (ATC S01BA01) via Open-House model

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Feb 28, 2027 · 184 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Dexamethason (ATC-Code nach WHO: S01BA01)

30/100

Score d'opportunité

High riskLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

30 / 100

Complexité

20 / 100

Facteurs de risque

The buyer may end the open-house procedure early if exclusive discount agreements are signed, which typically occur 8–1...

No minimum volumes; actual demand depends on patient prescriptions and pharmacy choices, which is unpredictable.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Weak opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Feb 2027
  • Supply of Dexamethasone pharmaceutical products under a non-exclusive discount agreement.
  • Participation in the Open-House model; no negotiations or exclusivity.
Afficher le résumé complet

Non-exclusive drug discount agreement (Rabattvereinbarung) under §130a Abs. 8 SGB V for the active ingredient Dexamethasone (ATC S01BA01) via an Open-House model. Published by AOK PLUS for pharmaceutical companies. No guaranteed volumes; contract ends 28 February 2027. All qualified companies can participate during the participation period.

Risques

The buyer may end the open-house procedure early if exclusive discount agreements are signed, which typically occur 8–1...

No minimum volumes; actual demand depends on patient prescriptions and pharmacy choices, which is unpredictable.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4 Abs. 18 AMG.
  • Must accept the confidentiality and silence obligations regarding the agreement content.

Eligibility

  • Must submit required declarations (exclusion grounds, Russia sanctions).

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria applicable; all qualified participants are accepted. The notice states that award criteria fields are placeholders due to technical reasons.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive drug discount agreement for Dexamethasone (ATC S01BA01) via Open-House model

One lot covering all Dexamethasone pharmaceutical products. Open-house model: no exclusivity, no negotiations, no minimum volumes. Agreement valid until 28 February 2027.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Feb 2026 - Feb 2027

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria applicable; all qualified participants are accepted. The notice states that award criteria fields are placeholders due to technical reasons.

Date limite

Deadline Feb 28, 2027

Détails de la procédure

Date de publication
22 Dec 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
857590-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30